Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Liabilities: 2013-2024

Historic Total Liabilities for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $845.2 million.

  • Amphastar Pharmaceuticals' Total Liabilities rose 8.80% to $889.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $889.5 million, marking a year-over-year increase of 8.80%. This contributed to the annual value of $845.2 million for FY2024, which is 3.24% down from last year.
  • Amphastar Pharmaceuticals' Total Liabilities amounted to $845.2 million in FY2024, which was down 3.24% from $873.5 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Total Liabilities registered a high of $873.5 million during FY2023, and its lowest value of $182.5 million during FY2020.
  • In the last 3 years, Amphastar Pharmaceuticals' Total Liabilities had a median value of $845.2 million in 2024 and averaged $644.0 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Total Liabilities decreased by 5.61% in 2022 and then skyrocketed by 309.46% in 2023.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Total Liabilities stood at $182.5 million in 2020, then rose by 23.83% to $226.0 million in 2021, then decreased by 5.61% to $213.3 million in 2022, then spiked by 309.46% to $873.5 million in 2023, then dropped by 3.24% to $845.2 million in 2024.